Speech-Language Pathologists in Gibsonia, PA Accepting Medicare

47 Speech-Language Pathologists found. Showing 41 - 47

St. Barnabas Medical Center, Inc. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5830 Meridian Rd, Gibsonia, PA 15044 Phone: 724-443-7231

Meris Hoppe, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 201 Field Brook Ct, Gibsonia, PA 15044 Phone: 608-886-7050

Elizabeth Rearigh, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5375 William Flynn Hwy Ste 8, Gibsonia, PA 15044 Phone: 724-444-5333

Rebekah Louise Nesbitt Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2400 Wildwood Rd, Gibsonia, PA 15044 Phone: 412-487-7771

Mrs. Kelly Rose Guarino, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5316 William Flynn Hwy, Gibsonia, PA 15044 Phone: 724-444-5333

Victoria Marie Smith, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5316 William Flynn Hwy, Gibsonia, PA 15044 Phone: 724-486-3077

Ms. Ranae Marie Ruffalo, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5465 Route 8, Gibsonia, PA 15044 Phone: 724-444-5333    Fax: 724-444-5335

News Archive

Baylor College of Medicine and UH team up for new research collaborations

Baylor College of Medicine and the University of Houston are teaming up for new research collaborations.

Innovative University of Surrey graduate start-up company wins Technology Strategy Board grant to drive NHS cost savings

Thoughtified Limited, a SETsquared start-up company created by graduates of the Department of Computing, University of Surrey has won a major grant from the Technology Strategy Board. The grant will enable the Surrey Research Park-based company to work in the development of a participatory sensing system that will improve the management of NHS patient records in remote patient treatment. The web and smartphone hybrid system will enable significant cost savings for the NHS, through improved utilisation of resources and reducing the inefficiencies that are typically incurred in the treatment of patients at home. The total finance raised for the project amounts to £94,000.

Polaris' ADI-PEG 20 novel anticancer drug inhibits growth of metastatic melanoma cells: Study

Physicians attending the annual meeting of the American Society of Clinical Oncology (ASCO) presented evidence that pegylated arginine deiminase (ADI-PEG 20), a novel anticancer drug that targets ASS(-) tumors, and which is being developed and manufactured by Polaris Group, was effective in inhibiting the growth of metastatic melanoma cells.

Better interventions needed to improve outcomes in young breast cancer patients

Breast cancer that occurs in young women is likely to be more aggressive and to require more intensive types of therapy with increased risk of long-term treatment-related toxicities. The unique and significant challenges and psychosocial concerns that women under 40 years of age with breast cancer face are discussed in a special article published in Journal of Adolescent and Young Adult Oncology, a multidisciplinary peer-reviewed publication from, Mary Ann Liebert, Inc., publishers.

Read more Medical News

› Verified 8 days ago

• 1
• 2
• 3(current)